Ionis Pharmaceuticals Inc (IONS)

02:12 AM

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade) - Seeking Alpha

02:12 AM

Apr 20, 2025

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way? - simplywall.st

Apr 20, 2025

Apr 18, 2025

Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock - Investing.com Australia

Apr 18, 2025

Apr 17, 2025

Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 17, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $19,291 in stock By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock - Investing.com

Apr 17, 2025

Apr 16, 2025

Lobbying Update: $90,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025

Apr 16, 2025

Ionis to hold first quarter 2025 financial results webcast - BioSpace

Apr 16, 2025

Apr 16, 2025

Ionis Q1 2025 Earnings Call: Key Date and Details for Investors Revealed - Stock Titan

Apr 16, 2025

Apr 12, 2025

Ionis Pharmaceuticals (IONS) Sees Price Target Cut by Morgan Sta - GuruFocus

Apr 12, 2025

Apr 12, 2025

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains? - MSN

Apr 12, 2025

Apr 11, 2025

Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com

Apr 11, 2025

Apr 11, 2025

Global Antisense & RNAi Therapeutics Market to Witness Massive - openPR.com

Apr 11, 2025

Apr 10, 2025

Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com

Apr 10, 2025

Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com

Apr 10, 2025

Apr 10, 2025

Transthyretin Amyloid Cardiomyopathy Treatment Market Set - openPR.com

Apr 10, 2025

Apr 09, 2025

Ionis at Needham Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com UK

Apr 09, 2025

Apr 08, 2025

Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright - MSN

Apr 08, 2025

Apr 08, 2025

HC Wainwright & Co. Initiates Coverage of Ionis Pharmaceuticals (IONS) with Buy Recommendation - MSN

Apr 08, 2025

Apr 07, 2025

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' - Benzinga

Apr 07, 2025

Apr 07, 2025

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Apr 07, 2025

Apr 07, 2025

Ionis Pharma stock hits 52-week low at $26.65 amid market challenges - Investing.com

Apr 07, 2025

Apr 07, 2025

H.C. Wainwright initiates coverage for Ionis Pharma with 'buy' rating citing pending drug launches - TradingView

Apr 07, 2025

Apr 07, 2025

H.C. Wainwright initiated coverage on Ionis Pharma with a new price target - Quantisnow

Apr 07, 2025

Apr 07, 2025

HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target - MarketScreener

Apr 07, 2025

Apr 07, 2025

H.C. Wainwright sets Ionis stock Buy rating, $45 target By Investing.com - Investing.com UK

Apr 07, 2025

Apr 04, 2025

Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com

Apr 04, 2025

Apr 03, 2025

Ionis to host expert panel discussion on sHTG - The Joplin Globe

Apr 03, 2025

Apr 03, 2025

Leading Medical Experts Reveal Latest Insights on Severe HTG Treatment Landscape - Stock Titan

Apr 03, 2025

Apr 02, 2025

Treatment-resistant Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com

Apr 02, 2025

Apr 02, 2025

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen

Apr 02, 2025

Apr 02, 2025

10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io

Apr 02, 2025

Apr 01, 2025

Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation - MSN

Apr 01, 2025

Mar 31, 2025

Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga

Mar 31, 2025

Mar 31, 2025

Redburn Atlantic initiated coverage on Ionis Pharma with a new price target - Quantisnow

Mar 31, 2025

Mar 31, 2025

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener

Mar 31, 2025

Mar 31, 2025

Ionis to present at upcoming investor conferences - The Joplin Globe

Mar 31, 2025

Mar 31, 2025

Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India

Mar 31, 2025

Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025

Mar 30, 2025

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN

Mar 30, 2025

Mar 29, 2025

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN

Mar 29, 2025

Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

RNA Biotechs: Current State And Outlook - Seeking Alpha

Mar 28, 2025

Mar 27, 2025

Ionis and Sobi agree on olezarsen commercialisation - Yahoo

Mar 27, 2025

Mar 26, 2025

Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa

Mar 26, 2025